EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

TAVR or SAVR? ChatGPT could help cardiologists decide
Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team.
Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR
Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.
EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes
Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.
Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves
Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.
New self-expanding TAVR valve shows promise
It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device.

Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique and the Evolut Pro and Pro+ TAVR valves, according to new findings presented at EuroPCR 2022 in Paris.

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

May 20, 2022

New data on cardiac damage before and after AVR suggests earlier treatment may be beneficial

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

May 19, 2022

Renal denervation is associated with improved blood pressure (BP) control and a reduced risk of adverse cardiovascular outcomes, according to two late-breaking clinical trials presented at EuroPCR 2022 in Paris. Both clinical trials focused on three-year data related to Medtronic’s Symplicity Spyral Renal Denervation (RDN) System, which was designed to lower BP through the use of a curling catheter that ablates overactive nerves.

Renal denervation improves blood pressure control, lowers risk of adverse cardiovascular outcomes

Two late-breaking clinical trials at EuroPCR 2022 in Paris focused on the potential benefits of renal denervation.

May 17, 2022

Clinical study of robotic-assisted cardiology solution reaches conclusion

“Robotics is, in all likelihood, the future of interventional cardiology," one specialist said. Full study results are expected in May.

January 11, 2022

Abbott’s TriClip a safe, effective treatment option for severe tricuspid regurgitation

According to the real-world analysis, treatment with TriClip was associated with no major adverse events and a procedural success rate of 100%.

May 21, 2021

Elective revascularization with PCI or CABG provides long-term cardiovascular benefits, new meta-analysis confirms

Researchers evaluated data from 25 different randomized clinical trials, sharing their findings virtually at EuroPCR 2021.

May 18, 2021

Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

May 18, 2021

Abbott’s TriClip reduces severity of tricuspid regurgitation in 86% of patients

Abbott’s transcatheter tricuspid valve repair system is a safe and effective approach to treating tricuspid regurgitation in heart patients with few other options, according to data published in The Lancet.

December 4, 2019

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

EuroPCR

TAVR or SAVR? ChatGPT could help cardiologists decide

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves

New self-expanding TAVR valve shows promise

Around the web